FDA Approves Lynparza-Mvasi Combo as Maintenance Therapy for Advanced Ovarian Cancer

Published by W Butcher on

The FDA approved new indications for olaparib (Lynparza, AstraZeneca) and bevacizumab-awwb (Mvasi, Amgen) to be used in combination for the maintenance treatment of adults with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.

Read More…

Categories: Uncategorized


Leave a Reply

Avatar placeholder

Your email address will not be published. Required fields are marked *